For each stock, we provide details on the highest individual sale, the number of insider sales exceeding $10 million ...

Shares of AbbVie Inc. (NYSE:ABBV – Get Free Report) shot up 0.6% on Wednesday after Wells Fargo & Company raised their price target on the stock from $210.00 to $240.00. Wells Fargo & Company ...

Bank of America raised AbbVie’s price target from $200 to $223 while maintaining a neutral rating. Other analysts have also ...

As Wall Street’s broader market averages continue to decline on Tuesday, following Monday’s significant sell-off, the idea of ...

Johnson & Johnson has rewarded shareholders with a quarterly dividend. As a Dividend King, it is the epitome of a steady and ...

BofA raised the firm’s price target on AbbVie (ABBV) to $223 from $200 and keeps a Neutral rating on the shares after the company and Gubra ...

Stock market investors have enjoyed strong annual returns over the past two years, but analysts caution that 2025 may not ...

COLUMBUS, Ga.-- ( BUSINESS WIRE )--The board of directors of Synovus Financial Corp. (NYSE: SNV) has declared the following ...

The Board of Directors of American Express Company (NYSE: AXP) has approved a $0.12, or 17 percent, increase in the quarterly dividend on the company’ ...

AbbVie partners with Gubra in a $2.2 billion deal to develop GUB014295, an amylin analog for obesity. The move marks AbbVie's entry into the competitive weight-loss market.

The Dividend Aristocrats 2025 list are US stocks that that have grown their dividend for 25+ years in a row and are in the ...

Shares of AbbVie Inc. (NYSE:ABBV – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the ...